Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?

1 Answers

Mednet Member

Radiation Oncology · David Geffen School of Medicine at UCLA

I believe this randomized trial does provide high-level evidence that adding 177Lu-PNT2002 prior to SBRT improves PFS compared with SBRT alone. If it were available off trial, yes, I would personally recommend it as an option. Currently, that is not the case.

We chose this sequencing because we thoug...